John McCafferty

Scientific Advisor

John McCafferty is a pioneer and inventor of antibody-phage display and co-founder of Cambridge Antibody Technology (now MedImmune, a fully owned subsidiary of AstraZeneca) for 12 years. In 2002 and after Cambridge Antibody Technology, John set up a group at the Sanger Institute which developed cutting edge protein expression and high throughput recombinant antibody isolation.

 

John then went on to head a research group within the Department of Biochemistry, University of Cambridge with a focus on identifying anti-receptor antibodies with therapeutic potential in cancer indications.

 

In 2012, John formed IONTAS, using phage display to develop novel antibody therapeutics. He also developed the next-generation Mammalian Display platform, a proprietary technology allowing discovery of IgG formatted antibodies directly from very large mammalian display libraries. To date, John has co-authored over 60 Peer Reviewed Publications.

This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.